Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Gilnature/iStock via Getty Images Nkarta Inc's (NASDAQ:NKTX) stock has pulled back over 50% from the highs of early March 2024. The name might find support in the $6 range looking at the chart, but to see if there might be some news flow to help that out, it's important to look at the company's pipeline of modified NK cells and upcoming catalysts. Data by YCharts NKTX's pipeline At the top of NKTX's pipeline is NKX019, an allogeneic (off the shelf) chimeric antigen receptor-NK cell, or CAR-NK, targeting ...